Novyra Pharmachem Limited announced that its Board of Directors has approved a proposal for the reduction of capital. The decision was taken during a meeting held on May 16, 2026, at the company's Registered Office. The proposal is pursuant to Sections 66 and other applicable provisions of the Companies Act, 2013, and is subject to approval from the BSE, shareholders, and other statutory authorities.

During the same meeting, the Board approved the Director's Report for the financial year ended March 31, 2026. The adoption of the Secretarial Audit Report for the same period, pursuant to Section 204(1) of the Companies Act, 2013, was also approved.

39th Annual General Meeting

The Board has convened the 39th Annual General Meeting (AGM) of the shareholders. The meeting is scheduled to be held on June 19, 2026, at 11:00 p.m. IST through Video Conferencing (VC). The purpose of the AGM is to seek shareholder approval on the proposed capital reduction and other business items.

To facilitate the AGM proceedings, the Register of Members and Share Transfer Books of the company will remain closed from June 13, 2026, to June 19, 2026 (both days inclusive).

Key Board Decisions

The Board approved the draft notice for the AGM and appointed Mrs. Rupal Patel, a Practicing Company Secretary, as the Scrutinizer for remote e-voting and voting at the AGM. The meeting commenced at 5:00 p.m. and concluded at 6:00 p.m.

Novyra Pharmachem Limited (formerly known as Bansisons Tea Industries Limited) has announced another revision to its board meeting schedule for the consideration of quarterly financial results. The company has now postponed its board meeting to April 29, 2026, marking the second rescheduling for the same agenda.

Latest Meeting Schedule Changes

The company initially scheduled the board meeting for April 18, 2026, which was first postponed to April 25, 2026. In the latest communication dated April 25, 2026, the company has further rescheduled the meeting to April 29, 2026.

Board Meeting Agenda

The rescheduled board meeting will address several key agenda items related to the company's financial performance for the fourth quarter of fiscal year 2026. The primary agenda includes:

• Consideration and approval of audited financial results for Q4FY26
• Review of auditor's report for the quarter and year ended March 31, 2026
• Certificate for unmodified opinion from auditors
• Other business matters as deemed necessary

Regulatory Compliance

The latest meeting revision has been communicated to BSE Limited in accordance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal communication was signed by Director Anilkumar Mohanbhai Amreliya (DIN: 11339148) on behalf of the company.

Company Background

Novyra Pharmachem Limited, formerly known as Bansisons Tea Industries Limited, operates from its registered office at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, Vasta Devdi Road, Surat, Gujarat. The company continues its business operations under the new name while maintaining compliance with all regulatory requirements and disclosure obligations.